Omnicare Reaches New 52-Week High (OCR)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Omnicare (NYSE: OCR) hit a new 52-week high Thursday as it is currently trading at $36.51, above its previous 52-week high of $36.48 with 972,984 shares traded as of 11:25 a.m. ET. Average volume has been one million shares over the past 30 days.

Omnicare has a market cap of $3.76 billion and is part of the services sector and wholesale industry. Shares are up 0.3% year to date as of the close of trading on Wednesday.

Omnicare, Inc. operates as a healthcare services company that specializes in the management of pharmaceutical care in the United States and Canada. The company has a P/E ratio of 25.5, below the average wholesale industry P/E ratio of 28.8 and above the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Omnicare as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Omnicare Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.